Sagimet Biosciences Inc. $SGMT Shares Acquired by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP increased its stake in shares of Sagimet Biosciences Inc. (NASDAQ:SGMT) by 99.4% during the first quarter, Holdings Channel.com reports. The institutional investor owned 271,217 shares of the company’s stock after buying an additional 135,178 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Sagimet Biosciences were worth $1,415,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. acquired a new stake in Sagimet Biosciences during the 4th quarter valued at approximately $30,000. Millennium Management LLC increased its stake in shares of Sagimet Biosciences by 6,484.7% in the third quarter. Millennium Management LLC now owns 776,377 shares of the company’s stock worth $5,326,000 after acquiring an additional 788,537 shares during the period. Bank of America Corp DE increased its stake in shares of Sagimet Biosciences by 158.6% in the third quarter. Bank of America Corp DE now owns 25,708 shares of the company’s stock worth $176,000 after acquiring an additional 15,765 shares during the period. Schonfeld Strategic Advisors LLC raised its holdings in shares of Sagimet Biosciences by 462.4% during the third quarter. Schonfeld Strategic Advisors LLC now owns 523,774 shares of the company’s stock worth $3,593,000 after purchasing an additional 430,644 shares during the last quarter. Finally, Raymond James Financial Inc. raised its holdings in shares of Sagimet Biosciences by 5.1% during the third quarter. Raymond James Financial Inc. now owns 278,246 shares of the company’s stock worth $1,909,000 after purchasing an additional 13,571 shares during the last quarter. 87.86% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Sagimet Biosciences news, insider Elizabeth Rozek sold 10,545 shares of the business’s stock in a transaction dated Monday, July 20th. The shares were sold at an average price of $7.76, for a total transaction of $81,829.20. Following the sale, the insider directly owned 224,414 shares in the company, valued at $1,741,452.64. This represents a 4.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director George Kemble sold 20,206 shares of the stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $9.95, for a total transaction of $201,049.70. Following the sale, the director owned 62,161 shares in the company, valued at approximately $618,501.95. This trade represents a 24.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 113,646 shares of company stock valued at $920,491 over the last 90 days. 11.50% of the stock is owned by company insiders.

Key Stories Impacting Sagimet Biosciences

Here are the key news stories impacting Sagimet Biosciences this week:

• Positive Sentiment: FDA clears Phase 3 acne study: The FDA accepted Sagimet’s Investigational New Drug application and issued a “Study May Proceed” letter for a U.S. Phase 3 trial of oral, once-daily denifanstat in moderate to severe acne. The trial is expected to begin in the second half of 2026 and enroll approximately 800 patients, including about 450 adolescents. This advances the company’s lead program into a late-stage study and could materially improve its commercial prospects if efficacy and safety are confirmed. FDA Study May Proceed letter and IND clearance
• Positive Sentiment: Citizens JMP raises price target: Citizens JMP increased its target for Sagimet from $12 to $29 and maintained a “Market Outperform” rating. The higher target reflects stronger expectations for denifanstat’s development following the FDA clearance. Citizens JMP price target update
• Positive Sentiment: Additional analyst support: Canaccord Genuity also issued a bullish outlook for SGMT, adding to generally positive Wall Street sentiment around the company’s pipeline and potential future appreciation. Canaccord Genuity Sagimet forecast
• Negative Sentiment: Continued operating losses: Sagimet reported a quarterly loss of $0.26 per share, slightly worse than the $0.25 analyst consensus, while HC Wainwright lowered its fourth-quarter loss estimate to $0.32 per share. The company remains dependent on clinical progress and likely future financing.
• Negative Sentiment: Insider selling: Director George Kemble sold 20,206 shares for approximately $201,050, reducing his direct ownership by 24.5%. Although the sale may be routine, it could temper investor sentiment following the recent rally. George Kemble insider sale

Sagimet Biosciences Stock Performance

Shares of Sagimet Biosciences stock opened at $10.55 on Friday. The business’s 50 day moving average price is $7.51 and its 200 day moving average price is $6.57. The company has a market cap of $343.77 million, a price-to-earnings ratio of -8.24 and a beta of 3.37. Sagimet Biosciences Inc. has a one year low of $4.50 and a one year high of $10.60.

Sagimet Biosciences (NASDAQ:SGMT) last issued its earnings results on Tuesday, August 11th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.01). On average, analysts predict that Sagimet Biosciences Inc. will post -1.15 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have commented on SGMT. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sagimet Biosciences in a report on Friday, July 17th. Oppenheimer reiterated an “outperform” rating on shares of Sagimet Biosciences in a research note on Friday, May 1st. Citigroup reissued a “market outperform” rating on shares of Sagimet Biosciences in a report on Friday. Guggenheim lowered their target price on Sagimet Biosciences from $27.00 to $25.00 and set a “buy” rating on the stock in a research note on Wednesday, April 29th. Finally, Canaccord Genuity Group raised their target price on Sagimet Biosciences from $49.00 to $56.00 and gave the stock a “buy” rating in a report on Wednesday. Seven research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $29.17.

Sagimet Biosciences Profile

Sagimet Biosciences (NASDAQ: SGMT) is a clinical-stage biotechnology company focused on developing novel therapies for fibrotic diseases. The company’s lead program, CM-101, is a first-in-class fusion protein designed to neutralize the chemokine CCL24 and interrupt key drivers of tissue fibrosis. Preclinical data have demonstrated CM-101’s potential to block fibrotic signaling pathways in multiple organ systems, and the company has advanced the program into early-stage clinical evaluation for indications such as nonalcoholic steatohepatitis and systemic sclerosis.

In addition to CM-101, Sagimet maintains a pipeline of preclinical candidates targeting inflammation-driven fibrotic processes.